to stop heart attacks by controlling inflammation—a different approach than lowering cholesterol level."> to stop heart attacks by controlling inflammation—a different approach than lowering cholesterol level." /> to stop heart attacks by controlling inflammation—a different approach than lowering cholesterol level." />
Myocardial Infarction or heart attack is a condition when blood flow at a heart muscle stops or decreases. The condition may occur due to various reasons, including excessive smoking, unhealthy food habits and others. It is more common in elderly people and may lead to death. Many treatment methods are available for the condition including various types of drugs and drug classes, surgeries and others. All the treatment methods may differ from individual to individual. High chances of reoccurrence are the major factors leading to the increasing usage of the prevention and treatment drugs.
Increasing research and development activities for safe drug development
Increasing research and development activities and growing technological advancements by various companies and government organizations are creating lucrative opportunities for market players. Various companies are emphasizing on developing innovative drugs. For instance, Novartis has developed a drug called canakinumab (ACZ885). It helps to prevent heart attacks by controlling inflammation—a different approach than lowering cholesterol level. According to Novartis, it reduced the cardiovascular risk by 25% in the trial presented at American Heart Association Session 2017.
Got questions about your regional growth of
Myocardial Infarction Market?
Just drop us a line or call on +1 646 480 7505
Asia Pacific is the fastest growing region in the forecast period
Myocardial infarction is one of the major diseases in China. It has become the major cause of an emergency over the past few decades owing to changing lifestyle and declining physical activity. In China, of men aged 30–44 years who die from cardiovascular disease, 46% of these deaths are attributable to tobacco. Additionally, there are more than 300 million smokers in China, nearly one-third of the world's total smoking population. This is projected to increase the risk of developing cardiovascular diseases, which is also expected to increase the demand for their demand. Thus, China is projected to witness considerable growth in the market during the forecast period.
Daiichi Sankyo, Co. Ltd is one of the leading providers of the medical solution of various segments including cardiovascular diseases such as myocardial infarction or heart attack and angina, kidney disease, and oncology segment across the globe. The company is differentiating itself with continuous innovations and expansion in various regions. Several products such as Efient and Ovisot have been launched by the company for the treatment of heart diseases over the last few years. The products have helped the company to strengthen its position in the market and also, to expand their product portfolio related to heart attack and other diseases.
Some of the prominent players in the market are Apotex Inc., AstraZeneca, Bayer AG, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Mylan N.V., Novartis AG, Par Pharmaceutical Companies, Inc., and Pfizer Inc.
Myocardial Infarction Market Segmentation
By Product Type
By Distribution channel
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast PeriodsView Full Report Buy This Report Now